By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nymox Pharmaceutical Corporation 

175 Bouchard
Suite 100
Dorval  Quebec  H9S 1B1  Canada
Phone: 514-636-3122 Fax:


Company News
Nymox (NYMX)'s New Phase III Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show 8/29/2016 11:45:29 AM
Taking a Closer Look at Nymox (NYMX)'s 'Overinflated' Prostate Drug Hype 8/29/2016 6:58:51 AM
Nymox Pharmaceutical (NYMX) Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction In Incidence Of Surgery 8/24/2016 11:19:36 AM
Nymox Pharmaceutical (NYMX) Announces Private Placements Of $2.24 Million 8/18/2016 10:00:27 AM
Nymox Pharmaceutical (NYMX) Announces Prostate Drug Progress 8/11/2016 10:59:20 AM
Nymox Pharmaceutical (NYMX) Files Current Financial Statements 1/4/2016 7:11:27 AM
Nymox Pharmaceutical (NYMX) Reports Results Of Prospective Cross-Over Study Of Fexapotide Treatment For Prostate Cancer 10/29/2015 12:21:52 PM
Nymox Pharmaceutical (NYMX) Announces Prostate Cancer Clinical Trial Will Complete Prospective 18 Month Post-Treatment Assessments 10/8/2015 10:48:54 AM
Nymox Pharmaceutical (NYMX) Announces Appointment Of James G. Robinson To Board Of Directors 7/30/2015 1:41:20 PM
Nymox Pharmaceutical (NYMX) July 27 Webcast Of New BPH Clinical Trial Results Posted Today Online 7/29/2015 7:54:33 AM